Trial Profile
The mucosal F. prausnitzii/E.coli index as a marker of microbiota improvement in ulcerative-colitis dysbiosis after treatment with mesalazine-MMX (Mezavant)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Sep 2015
Price :
$35
*
At a glance
- Drugs Mesalazine (Primary)
- Indications Dysbiosis; Ulcerative colitis
- Focus Therapeutic Use
- 08 Sep 2015 New trial record